文献速递关节外科

全膝关节置换术前仅三个月司美格鲁肽暴露与2型糖尿病患者术后不良事件减少相关

As Few as Three Months of Preoperative Semaglutide Exposure Prior to Total Knee Arthroplasty Is Associated With Reduced Postoperative Adverse Events in Patients Who Have Type II Diabetes.
PubMed 文献 · J Arthroplasty · 2025-08-08

该回顾性队列研究从全国数据库纳入2型糖尿病患者,按全膝关节置换术前司美格鲁肽暴露时长分为6至12个月、3至6个月、2至3个月、1至2个月和不足1个月五组,每组与不使用司美格鲁肽的对照按1:4匹配。结果显示,术前暴露2至3个月及以上时严重不良事件几率显著降低(OR 0.25,P < 0.001),任何暴露时长均与轻微不良事件降低相关(不足1个月组OR 0.16,P < 0.001)。作者认为术前3个月暴露似乎足以减少术后不良事件。

要点

  • 术前司美格鲁肽暴露不足1个月组轻微不良事件OR 0.16(P < 0.001),所有更长暴露时长均一致降低。
  • 术前暴露至少2至3个月组严重不良事件OR 0.25(P < 0.001),更短暴露未见显著降低。
  • 作者认为术前3个月司美格鲁肽暴露似乎足以减少轻微和严重术后不良事件。

核心结论

  • 全膝关节置换术前3个月司美格鲁肽暴露似乎足以降低轻微和严重术后不良事件。
  • 这些观察性发现不能建立因果关系,但具有重要临床意义,并为旨在优化术前护理路径的前瞻性分析奠定基础。

研究设计与样本

  • 回顾性队列研究,从全国数据库识别2型糖尿病患者,按全膝关节置换术前司美格鲁肽暴露时长分为6至12个月、3至6个月、2至3个月、1至2个月和不足1个月五组。
  • 每组与不使用司美格鲁肽的2型糖尿病全膝关节置换对照按1:4匹配。
  • 匹配后6至12个月、3至6个月、2至3个月、1至2个月和不足1个月组分别纳入745、451、210、113和91例。
  • 采用多变量逻辑回归比较90天严重不良事件(手术部位感染、脓毒症、静脉血栓栓塞、心脏事件、胰腺炎)和轻微不良事件(伤口裂开、血肿、输血、急性肾损伤、肺炎、尿路感染)。

主要发现

  • 术前不足1个月开始司美格鲁肽组轻微不良事件OR 0.16(P < 0.001),所有更长暴露时长均与轻微不良事件降低一致相关(P < 0.001)。
  • 术前至少2至3个月暴露组严重不良事件OR 0.25(P < 0.001),更短暴露时长未见严重不良事件显著降低。

局限性

  • 原文指出这些观察性发现不能建立因果关系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Semaglutide, a glucagon-like peptide-1 receptor agonist, has been increasingly used for the management of type II diabetes mellitus (T2DM). Although recent literature suggests semaglutide may reduce postoperative total knee arthroplasty (TKA) complications, to our knowledge, the minimum duration of semaglutide exposure associated with superior outcomes has never been studied. METHODS: A retrospective cohort of patients with T2DM was identified from a national database and stratified into one of five mutually exclusive groups of semaglutide exposure before TKA: six to 12 months, three to six months, two to three months, one to two months, or less than one month. Each cohort was individually matched 1:4 with non-semaglutide T2DM TKA controls. The occurrence of 90-day severe adverse events including surgical site infection, sepsis, venous thromboembolism, cardiac events, pancreatitis, and minor adverse events (MAEs) including wound dehiscence, hematoma, transfusion, acute kidney injury, pneumonia, and urinary tract infection, was compared using multivariable logistic regression. RESULTS: After matching, patient cohorts with preoperative semaglutide exposure for six to 12 months, three to six months, two to three months, one to two months, and less than one month included 745, 451, 210, 113, and 91, respectively. Patients initiating semaglutide less than one month before TKA revealed lower odds of MAE (odds ratio 0.16, P < 0.001), with consistent reduction in MAE across all increased exposure durations (P < 0.001 for all). Reduced odds of severe adverse events were significant after a minimum of two to three months of preoperative exposure (odds ratio 0.25, P < 0.001). CONCLUSIONS: A 3-month period of preoperative semaglutide exposure before TKA appears to be sufficient to reduce both minor and severe postoperative adverse events. Although these observational findings cannot establish causation, they have major clinical implications and lay the foundation for prospective analysis aimed at optimizing preoperative care pathways.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Seddio AE, Vasudevan RS, Gouzoulis MJ, et al. As Few as Three Months of Preoperative Semaglutide Exposure Prior to Total Knee Arthroplasty Is Associated With Reduced Postoperative Adverse Events in Patients Who Have Type II Diabetes. J Arthroplasty. 2025. PMID: 40784425. doi:10.1016/j.arth.2025.08.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。